Contracts › 75N93026F00003
75N93026F00003: Performing Fda 510K Enabling Studies for a Diagnostic to Detect Ciprofloxicin Resistance or Susceptability
Awarded to Mriglobal by National Institutes of Health (NIH).
$1.6Mobligated
$1.6Mpotential value
10 March 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93026F00003 |
|---|---|
| Vehicle | 75N93023D00017 |
| Awardee | Mriglobal |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MO |
| Period of performance | 04 May 2026 to 10 March 2027 |
| Potential end | 10 March 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record